Drug Profile
KSB 304
Latest Information Update: 28 Jul 2004
Price :
$50
*
At a glance
- Originator University of Medicine & Dentistry of New Jersey
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (parenteral)
- 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
- 28 Aug 2003 DanioLabs and KS Biomedix have entered into an agreement to investigate a colon epithelial protein in the UK for ulcerative colitis